Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide

Hyderabad, India September 2, 2021 and Mississauga, ON, CAN. September 1, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.

Read the Full Release

Member Forum

September 14 - 16, 2021

MORE INFO

Boot Camp

November 23 - 24, 2021

MORE INFO

Executive Conference

January 11 - 13, 2021

MORE INFO

Annual Conference

May 3 - 5, 2021

MORE INFO